Pills blog

Danilon

Category: Antibiotics

Description

Noroxin is used to treat bacterial infections of the prostate and urinary tract. Noroxin also treats gonorrhea.

Active Ingredient: norfloxacin

Noroxin (Danilon) as known as: Alenbit, Ambigram, Amicrobin, Apiflox, Apirol, Asudufe, Azo uroflam, Baccidal, Bacfamil, Bacteriotal, Bactracid, Bafurokisaru, Barazan, Barocul, Basteen, Baxicin, Bexinor, Bio tarbun, Biscolet, Blemalart, Chibroxin, Chibroxine, Chibroxol, Co norfloxacin, Constilax, Danilon, Diperflox, Effectsal, Epinor, Esclebin, Espeden, Firin, Flobarl, Flocidal, Flossac, Flox, Floxamed, Floxamicin, Floxatral, Floxatrat, Floxen, Floxinol, Fluseminal, Foxgoria, Grenis, Gyrablock, H-norfloxacin, Janacin, Lemorcan, Lexiflox, Lexinor, Lorcamin, Loxone, Mariotton, Memento nf, Menorox, Microxin, Mitatonin, N-flox, Naflox, Nalion, Negaflox, Negalflex, Niterat, Noflo, Nofloxan, Nofocin, Nofxan, Nolicin, Noprose, Nor, Noracin, Norax, Noraxin, Norbactin, Norcozine, Norfacin, Norfen, Norflodal, Norflogen, Norflohexal, Norflok, Norflol, Norflomax, Norflosal, Norflostad, Norflox, Norflox-ct, Norfloxacina, Norfloxacine, Norfloxacino, Norfloxacinum, Norfluxx, Norilet, Normax, Norocin, Noroxine, Norsol, Norzen, Notler, Noxacin, Nufloxib, Oranor, Ovinol, Parcetin, Pharex norfloxacin, Pistofil, Quinabic, Renor, Renoxacin, Respexil, Rexacin, Ritromine, Sebercim, Senro, Setanol, Shinun, Sinobid, Sofasin, Stbanil, Taflox, Theanorf, Trizolin, Unasera, Uricin, Uriflox, Uritracin, Uritrat, Uro-linfol, Uro-plus, Urobacid, Urobiotic, Uroctal, Urodixil, Urodol, Uroflox, Urofos, Uronovag, Uroquin, Uroseptal, Urospes-n, Urotem, Uroxacin, Utibid, Uticina, Utinor, Vefloxa, Vetamol, Wenflox, Xaflor, Xasmun, Zoroxin

NOAH Compendium of Animal Medicines: Danilon Equidos Granules for top dressing - Contra-indications, warnings, etc

Danilon Equidos 1.5g Granules for top dressing

Contra-indications, warnings, etc

Do not use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Do not administer to horses prior to taking part in a competition. See Further Information section.

Do not administer to animals with renal, hepatic or cardiac disorders, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Avoid use in dehydrated, hypovolemic or hypotensive animals as there is an increased risk of renal failure. Do not restrict the consumption of water during treatment.

Use in very young (less than 12 weeks) or aged animals and ponies may involve additional risk. Ensure accurate calculation of dose according to body weight and closely monitor clinical response.

NSAIDs can inhibit phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial treatment should also be used.

Studies have not been carried out in the horse to establish safe use during pregnancy and lactation.

After continued use, or when used at high doses, gastro-intestinal changes may occur. Occasionally, blood dyscrasias and renal alterations may be found, especially in animals with restricted access to water.

In case of accidental continuous overdose, the following symptoms may occur: thirst, depression, anorexia and weight loss; gastro-intestinal disorders (irritation, ulcers, diarrhoea and faecal blood); altered blood profiles and haemorrhages; hypoproteinaemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse; renal failure and fluid retention.

If signs of intolerance appear, discontinue administration and apply symptomatic treatment.

A slow intravenous infusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product.

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with other highly bound drugs (eg. sulphonamides, warfarin) or may itself be displaced to produce an increase of non-bound pharmacologically active concentrations which could lead to toxic effects. Concurrent administration of other highly bound drugs will lead to an increase of non-bound plasma concentrations, which may lead to toxic effects. Drug compatability must be closely monitored when adjunctive therapy is required.

Do not administer concurrently with other NSAIDs or within 24 hours of other NSAIDs.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Wear suitable gloves. Wash hands after use. Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing with feed. In case of accidental contact with eyes, wash immediately with plenty of clean water. In case of accidental ingestion, seek medical advice immediately and show the product information leaflet to the physician.

For animal treatment only. Keep out of the reach and sight of children

Other articles

Buy Danilon Equidos Sachets PK 60

DANILON EQUIDOS SACHETS 1.5G Description:

Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.

Dosage and administration - Danilon

For oral administration. When added to a portion of feed the product will be accepted by most horses. Ensure free access to drinking water during treatment. Do not exceed the stated dose or duration of treatment. Dosage should be kept to a minimum for alleviation of symptoms

For a 480 kg horse: administer 2 sachets twice daily for 2 days (equivalent to 12.5 mg suxibuzone/kg/day).

Follow by administering 1 sachet twice daily for 3 days (equivalent to 6.25 mg suxibuzone/kg/day).

Thereafter, administer 1 sachet daily (equivalent to 3.1 mg suxibuzone/kg/day) or on alternate days or the minimum dose necessary for a satisfactory clinical response.

Administer half the recommended dose for horses. Adjust the dose carefully according to bodyweight.

For a 240 kg pony: administer 1 sachet daily for 2 days (equivalent to 6.25 mg of suxibuzone/kg/day).

Follow by administering ½ sachet daily for 3 days (equivalent to 3.1 mg of suxibuzone/kg/day) or 1 sachet each day on alternate days. Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical response.

Further administration advice

For administration of less than one sachet, use the measuring scoop provided. One full level scoop contains 5 g granules (equivalent to 1/2 sachet) and up to the green line level contains 2.5 g granules (equivalent to 1/4 sachet). Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of the clinical effect. It is advisable not to feed hay immediately prior to, or with Danilon Equidos. If no clinical response is evident after 4-5 days of treatment, discontinue treatment and reconsider the diagnosis.

Read more.

Contra-indications, warnings, etc

Do not use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Do not administer to horses prior to taking part in a competition. See Further Information section.

Do not administer to animals with renal, hepatic or cardiac disorders, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Avoid use in dehydrated, hypovolemic or hypotensive animals as there is an increased risk of renal failure. Do not restrict the consumption of water during treatment.

After continued use, or when used at high doses, gastro-intestinal changes may occur. Occasionally, blood dyscrasias and renal alterations may be found, especially in animals with restricted access to water.

Use in very young (less than 12 weeks) or aged animals may involve additional risk. Ensure accurate assessment of dose to body weight and closely monitor clinical response.

Studies have not been carried out in the horse to establish safe use during pregnancy and lactation.

NSAIDs can inhibit phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial treatment should also be used.

In case of accidental continuous overdose, the following symptoms may occur: thirst, depression, anorexia and weight loss; gastro-intestinal disorders (irritation, ulcers, diarrhoea and faecal blood); altered blood profiles and haemorrhages; hypoproteinaemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse; renal failure and fluid retention.

If signs of intolerance appear, discontinue administration and apply symptomatic treatment.

A slow intravenous infusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product.

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with other highly bound drugs eg. (sulphonamides, warfarin) or may itself be displaced to produce an increase of non-bound pharmacologically active concentrations which could lead to toxic effects. Concurrent administration of other highly bound drugs will lead to an increase of non-bound plasma concentrations, which may lead to toxic effects. Drug compatability must be closely monitored when adjunctive therapy is required.

Do not administer concurrently with other NSAIDs or within 24 hours of other NSAIDs.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Wear suitable gloves. Wash hands after use. Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing with feed. In case of accidental contact with eyes, wash immediately with plenty of clean water. In case of accidental ingestion, seek medical advice immediately.

For animal treatment only. Keep out of the reach and sight of children

After opening a sachet re-seal as well as possible between doses. Once opened, use within 7 days. This medicinal product does not require any special storage conditions

Carton with 18 or 60 polyethylene lined sachets containing 10 g granules. A 5g scoop (when level) with a 2.5g increment is provided

Do not administer to horses prior to taking part in a competition

Suxibuzone is a prohibited substance under international equine competition rules. Treatment with Danilon Equidos should be stopped for a suitable time prior to competing. Follow RCVS guidance on elimination times for various anti-inflammatory drugs.

Suxibuzone is a NSAID with anti-inflammatory, antipyretic and analgesic properties and low ulcerogenic potential. Its mechanism of action is based on the inhibition of cyclo-oxygenase. The therapeutic effects are mainly due to the inhibition of the biosynthesis of prostaglandins, which act as peripheral mediators of pain and trigger the synthesis of endogenous pyrogens and mediators in the inflammatory process. It also inhibits platelet aggregation. After oral administration, suxibuzone is readily absorbed and it is metabolized by the hepatic microsomal system; these active metabolites produce suxibuzone's therapeutic effect.

As happens with other NSAIDs, the duration of the clinical response is much longer than the plasma half-life. Significant concentrations of both active metabolites are found in synovial fluid for at least 24 hours after administration.

Marketing Authorisation Holder (if different from distributor)

Laboratorios Dr. ESTEVE, S.A.

Avda. Mare de Deu de Montserrat, 221

Marketing authorisation number

Danilon diseases

Danilon Equidos Sachets

You will receive VioPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount. Ts & Cs apply.

We will need a valid prescription from your vet before we can dispatch an order for this item. Information

Product Details

Danilon Equidos comes in sachets of yellow, odourless granules to add to the food of horses. It has to be prescribed by your vet and is used to treat pain and inflammation associated with osteoarthritis, degenerative joint disease, musculo-skeletal injuries and conditions such as bursitis and laminitis. One sachet is an adequate starting dose for a 240kg pony. A horse weighing 480kg needs two sachets on the first day. On the following three days a half dose is all that is required, and then afterwards this dose can be given daily or on alternate days, depending on the response. A scoop is provided within the carton to enable half sachets to be measured out for more accurate dosing of different sized equines. Danilon Equidos should not be given to any equine which might go for human consumption in future. It is also a prohibited substance under international equine competition rules. Treatment with Danilon should be stopped for a suitable time before competing to allow the drug to clear.

Presentation

Sachets containing 10 g of yellow, odourless granules for top dressing. Each sachet contains 1.5 g of Suxibuzone (microencapsulated). Also contains quinoline yellow (E104)

Uses

Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.

Dosage and administration

For oral administration. When added to a portion of feed the product will be accepted by most horses. Ensure free access to drinking water during treatment. Do not exceed the stated dose or duration of treatment. Dosage should be kept to a minimum for alleviation of symptoms.

Horses

For a 480 kg horse: administer 2 sachets twice daily for 2 days (equivalent to 12.5 mg suxibuzone/kg/day).

Follow by administering 1 sachet twice daily for 3 days (equivalent to 6.25 mg suxibuzone/kg/day).

Thereafter, administer 1 sachet daily (equivalent to 3.1 mg suxibuzone/kg/day) or on alternate days or the minimum dose necessary for a satisfactory clinical response.

Ponies

Administer half the recommended dose for horses. Adjust the dose carefully according to bodyweight.

For a 240 kg pony: administer 1 sachet daily for 2 days (equivalent to 6.25 mg of suxibuzone/kg/day).

Follow by administering ½ sachet daily for 3 days (equivalent to 3.1 mg of suxibuzone/kg/day) or 1 sachet on alternate days. Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical response.

Further administration advice

For administration of less than one sachet, use the measuring scoop provided. One full level scoop contains 5 g granules (equivalent to 1/2 sachet) and up to the green line level contains 2.5 g granules (equivalent to 1/4 sachet). Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of the clinical effect. It is advisable not to feed hay immediately prior to, or with Danilon Equidos. If no clinical response is evident after 4-5 days of treatment, discontinue treatment and reconsider the diagnosis.

Contra-indications, warnings, etc

Do not use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.

Do not administer to horses prior to taking part in a competition. See Further Information section.

Do not administer to animals with renal, hepatic or cardiac disorders, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Avoid use in dehydrated, hypovolemic or hypotensive animals as there is an increased risk of renal failure. Do not restrict the consumption of water during treatment.

After continued use, or when used at high doses, gastro-intestinal changes may occur. Occasionally, blood dyscrasias and renal alterations may be found, especially in animals with restricted access to water.

Use in very young (less than 12 weeks) or aged animals may involve additional risk. Ensure accurate assessment of dose to body weight and closely monitor clinical response.

Studies have not been carried out in the horse to establish safe use during pregnancy and lactation.

NSAIDs can inhibit phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infections, appropriate antimicrobial treatment should also be used.

In case of accidental continuous overdose, the following symptoms may occur: thirst, depression, anorexia and weight loss; gastro-intestinal disorders (irritation, ulcers, diarrhoea and faecal blood); altered blood profiles and haemorrhages; hypoproteinaemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse; renal failure and fluid retention.

If signs of intolerance appear, discontinue administration and apply symptomatic treatment.

A slow intravenous infusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product.

Interactions

Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with other highly bound drugs eg. (sulphonamides, warfarin) or may itself be displaced to produce an increase of non-bound pharmacologically active concentrations which could lead to toxic effects. Concurrent administration of other highly bound drugs will lead to an increase of non-bound plasma concentrations, which may lead to toxic effects. Drug compatability must be closely monitored when adjunctive therapy is required.

Do not administer concurrently with other NSAIDs or within 24 hours of other NSAIDs.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Operator warnings

Wear suitable gloves. Wash hands after use. Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing with feed. In case of accidental contact with eyes, wash immediately with plenty of clean water. In case of accidental ingestion, seek medical advice immediately.

For animal treatment only. Keep out of the reach and sight of children

Pharmaceutical precautions

After opening a sachet re-seal as well as possible between doses. Once opened, use within 7 days. This medicinal product does not require any special storage conditions

Danilon Drug Information, Indications - Other Medicaments on

Danilon Drug Information Danilon forms, composition and dosages: Indications, usages and classification codes:

There is an additional general information about this medication active ingredient ibuprofen:

Pharmacological action

NSAIDs, a derivative of phenylpropionic acid, ibuprofen has anti-inflammatory, analgesic and antipyretic effect.
The mechanism of action is associated with inhibition of COX activity - the main enzyme metabolism of arachidonic acid, which is a precursor of prostaglandins, which play a major role in the pathogenesis of inflammation, pain and fever. Analgesic effect is due to both peripheral (indirectly, through suppression of prostaglandin synthesis), and a central mechanism (due to inhibition of prostaglandin synthesis in the central and peripheral nervous system). Inhibits platelet aggregation.
For topical use anti-inflammatory and analgesic action. Reduces morning stiffness, increased the amount of motion in joints.

Pharmacokinetics

When oral administered ibuprofen almost completely absorbed from the gastrointestinal tract. Simultaneous food intake slows the rate of absorption. Metabolised in the liver (90%). T1 / 2 is 2-3 hours.
80% of the dose excreted in urine mainly as metabolites (70%), 10% - unchanged, 20% eliminated through the intestine in the form of metabolites.

Why is Danilon by Allergan prescribed?

Inflammatory, degenerative diseases of joints and spine (including rheumatic and rheumatoid arthritis, ankylosing spondylitis, osteoarthritis), articular syndrome in patients with acute gout, psoriatic arthritis, ankylosing spondylitis, tendonitis, bursitis, sciatica, traumatic inflammation of soft tissue and musculoskeletal apparatus. Neuralgia, myalgia, pain in infectious and inflammatory diseases of ENT organs, bursitis, algomenorrhea, headache and toothache. Fever in infectious and inflammatory diseases.

Dosage and administration

Setting individually, depending on etiology of disease, severity of clinical manifestations. When administered rectally or adult single dose of 200-800 mg, the frequency of reception - 3-4; for children - 20-40 mg / kg in divided doses.
Topical applied within 2-3 weeks.
The maximum daily dose for adults when administered oral or rectally or is 2.4 g.
Oral, after a meal. Rheumatoid arthritis - by 0.8 g 3 times a day in osteoarthrosis and ankylosing spondylitis - by 0.4-0.6 g 3-4 times a day, in juvenile rheumatoid arthritis - at 30-40 mg / kg / day in several stages.
When soft tissue injuries, sprains - 1.6-2.4 g / day in divided doses.
At moderate pain syndrome - 1.2 g per day.

Danilon by Allergan side effects

Digestive system: frequently - nausea, anorexia, vomiting, epigastric discomfort, diarrhea, possibly the development of erosive and ulcerative lesions of the gastrointestinal tract; rare - bleeding from the gastrointestinal tract, long-term use possible liver problems.
Central nervous system and peripheral nervous systems: frequently - headache, dizziness, sleep disturbances, agitation, visual impairment.
Hemopoietic system: long-term use may be anemia, thrombocytopenia, agranulocytosis.
Urinary tract: long-term use possible renal dysfunction.
Allergic reactions: often - skin rash, Quincke's edema, rarely - aseptic meningitis (usually in patients with autoimmune diseases), bronchospasm syndrome.
Local reactions: when topical used may be hyperemia of the skin, burning or tingling.

Contraindications

Erosive-ulcerative lesions in the gastrointestinal tract exacerbation, diseases of the optic nerve, "aspirin triad", hemodyscrasia, pronounced renal dysfunction and / or liver, children age (to 6 years), hypersensitivity to ibuprofen.

Using during pregnancy and breastfeeding

Do not use ibuprofen in the III trimester of pregnancy. Application I and II trimesters of pregnancy is justified only in cases where the expected benefit to the mother than the possible harm to the fetus.
This medication ibuprofen in small amounts excreted in breast milk. Possible using in lactation for pain and fever. If necessary, prolonged use or use in high doses (800 mg / 24 h), should decide on the termination of breastfeeding.

Special instructions

Precautions are used with the attendant liver and kidney diseases, chronic heart failure, with dyspeptic symptoms before treatment, immediately after surgery, with indications of a history of gastrointestinal bleeding in diseases of the digestive tract, allergic reactions associated with NSAID intake.
In the course of treatment requires systematic monitoring of the liver and kidneys, peripheral blood picture.
It should not be applied externally to the damaged skin.

Danilon by Allergan drug interactions

With simultaneous use of ibuprofen reduces the effect of antihypertensive agents (ACE inhibitors, beta-blockers), diuretics (furosemide, hypothiazide).
With the simultaneous use of anticoagulants may enhance their action.
With simultaneous application of SCS increases the risk of side effects from the gastrointestinal tract.
With the simultaneous application of ibuprofen may displace from compounds with plasma proteins indirect anticoagulants (acenocoumarol), derivatives of hydantoin (phenytoin), oral hypoglycemic drugs sulfonylurea derivatives.
With the simultaneous use of amlodipine may be a slight reduction of antihypertensive action of amlodipine, with acetylsalicylic acid - decreased concentration of ibuprofen in blood plasma, with baclofen - described a case of toxic gain of baclofen.
When applied simultaneously with warfarin may increase bleeding time, were also observed microhematuria, bruises with hydrochlorothiazide - perhaps a slight reduction of antihypertensive action of hydrochlorothiazide, captopril - may reduce antihypertensive effect of captopril, with cholestyramine - moderately decrease absorption of ibuprofen.
With simultaneous application of lithium carbonate increased the concentration of lithium in blood plasma.
With simultaneous application of magnesium hydroxide increases the initial absorption of ibuprofen, with methotrexate - increases the toxicity of methotrexate.

Danilon by Allergan in case of emergency / overdose

In case of overdose, call your local poison control center or emergency services.
Symptoms of overdose may include: dizziness; fast eye movements that you cannot control; slow breathing or short periods of time without breathing; blue color around the lips, mouth, and nose.

Storage conditions

In a dry, protected from light place, at temperatures below 25°C. Expiration date for ibuprofen: 3 years.

PLEASE, BE CAREFUL!

Be sure to consult your doctor before taking any medication!

Danilon Equidos Sachets - Danilon for Horses - Danilon (Bute) Sachets

Danilon There is 1 product. Danilon sachets for horses

What is Danilon Equidos.
Danilon Equidos is a non-steroidal anti-inflammatory drug very similar to Bute for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. Danilon contains Suxibuzone, which is sim.

Danilon sachets for horses

What is Danilon Equidos.
Danilon Equidos is a non-steroidal anti-inflammatory drug very similar to Bute for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. Danilon contains Suxibuzone, which is similar to Bute for Horses, but is sugar coated to make it more palatable. Danilon is also believed to be easier on the Horse's stomach i.e. less risk of ulcers. Danilon is a prescription-only medication and is only available on receipt of a valid veterinary prescription.

How does Danilon for horses work?
Danilon is a prodrug of the non steroidal anti inflammatory drug phenylbutazone (sometimes referred to as bute). Danilon is a member of a group of anti-inflammatory medications known as non-steroidal anti-inflammatory drugs (NSAIDS). These medicines inhibit enzymes called cyclo-oxygenase or COX 1 and 2 which are involved in protective mechanisms within the body and inducing inflammation respectively. NSAIDs generally aim to be COX-2 selective.

Danilon is more palatable than other pain killing medications and will be readily eaten with the horse's normal hard feed.

What conditions are Danilon equidos used to treat?
Danilon is an effective teatment for inflammatory pain. Common causes of inflammation in horses are osteoarthritis or degenerative joint disease, laminitis, bursitis, ligament or tendon sprains and strains. Danilon is also useful for treating post-operative pain or as pain relief following wounds and injuries.

A Veterinary Prescription is required for Danilon

Danilon Equidos is a medication for horses that is used to treat muscular pain and inflammation, such as that which can occur as part of conditions such as laminitis, osteoarthritis, bursitis and soft tissue inflammations. Danilon is classed as a non-steroidal anti-inflammatory drug, or NSAID.

Danilon comes in powder form, in individual sachets for addition to food.

More about Danilon

The active ingredient in Danilon is called Suxibuzone, which is a prodrug of phenylbutazone, meaning that when Danilon is administered it is inactive, becoming activated by the horse’s normal digestive and metabolic processes.

Suxibuzone is metabolised by the liver, turning it into a form of phenylbutazone and oxyphenbutazone, both of which are effective anti-inflammatory and analgesic agents. Administration of Danilon as opposed to phenylbutazone itself has been shown to potentially produce less incidences of stomach upsets and digestive problems in horses prescribed such medications.

The action of Danilon is anti-inflammatory to reduce swelling, analgesic to reduce pain, and antipyretic to reduce inflammation, making it highly effective in the treatment and management of conditions and injuries that present with a range of different exacerbating factors, such as laminitis and osteoarthritic conditions.

How is Danilon administered?

Danilon is provided in powder form in sealed sachets, for addition to feed. The dosage guidelines for Danilon are as follows:

Using Danilon in Horses:

For a horse weighing 480kg, give two sachets twice per day for the initial two days of treatment. Following this, administer one sachet twice per day for another three days. After this time, administer one sachet once per day, or one sachet every other day, at the minimum dose necessary to provide relief.

Using Danilon in Ponies:

Ponies should be administered around half of the recommended dose of that for horses, adjusted to take into account the weight of the pony.

For a pony weighing 240kg, give one sachet daily for the initial two days, then half a sachet daily for another three days, or one sachet per day on alternate days. After the initial treatment period, reduce dosage to the lowest possible level to provide relief.

If less than one sachet is used per dose, use the provided measuring scoop to correctly measure out the right dosage. Hay should not be fed with Danilon, nor immediately prior to its administration, as hay can delay the absorption of Suxibuzone by the body, delaying its effectiveness.

If treatment with Danilon does not generate a marked improvement in condition within five days of beginning treatment, the treatment should be reviewed by your vet.

What are the advantages of Danilon?

Danilon is easy to administer to horses, and is generally well received when mixed into food. Because Danilon comes in powder form, dosages can be adjusted easily in order to fine-tune the treatment to suit the needs of each individual horse or pony.

Danilon’s active ingredient is activated by metabolism, which leads to a reduced risk of gastrointestinal side effects when compared to other forms of phenylbutazone delivery.

What horses can be given Danilon?

Danilon should only be given to the horse or pony for which it has been prescribed, and should be dosed carefully and given in accordance with your vet’s guidance.

Danilon should not be administered to horses or ponies taking part in competition, due to regulations regarding the use of phenylbutazone-based medications in competitive sport.

Danilon should not be given to horses intended for human consumption, and if Danilon has been administered, international equine passport legislation requires that the horse in question must be formally declared as such.

Water should be freely available to horses treated with Danilon, and treatment with Danilon should be avoided in horses that are dehydrated, hypotensive or hypovolemic, or classed as being at risk of renal failure. Danilon should not be prescribed to horses diagnosed with hepatic, renal or cardiac disorders, or those that may have gastrointestinal ulcers or bleeds.

The potential risk factors of Danilon are increased in horses under the age of twelve weeks or those that are elderly, and special care should be taken when treating such horses. Effective treatment with the minimal risk of problems depends heavily on ensuring that the right dose is calculated and administered correctly for each individual horse’s bodyweight, and that they are carefully monitored and their dosage reduced when possible.

How can I get Danilon?

Danilon is a POM-V medication, meaning that it is only available with a prescription from your veterinary surgeon. Your vet will assess the condition of your horse or pony and the underlying condition that necessitates the prescription of NSAIDs, and make an informed decision on the best medication to proceed with.

Once your vet has provided you with a prescription for Danilon, this can be used to purchase the medication online, and Danilon should then be administered in strict accordance with the guidance provided on the packaging, and any additional caveats that your veterinary surgeon has provided for you.

MIN — Diophindane, general information, pharmacology, Diophindane for patients, Diophindane interactions, Diophindane contraindications, additio

Diophindane Diophindane - General Information

An indandione that has been used as an anticoagulant. Diophindane has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)

Pharmacology of Diophindane

Diophindane thins the blood by antagonizing vitamin K which is required for the production of clotting factors in the liver. Anticoagulants such as Diophindane have no direct effect on an established thrombus, nor do they reverse ischemic tissue damage (damage caused by an inadequate blood supply to an organ or part of the body). However, once a thrombus has occurred, the goal of anticoagulant treatment is to prevent further extension of the formed clot and prevent secondary thromboembolic complications which may result in serious and possibly fatal sequelae. Diophindane has actions similar to warfarin, but it is now rarely employed because of its higer incidence of severe adverse effects.

Additional information about Diophindane

Diophindane Indication: For the treatment of pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, mural thrombosis, and thrombophili. Also used for anticoagulant prophylaxis.
Mechanism Of Action: Diophindane inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Depression of three of the four vitamin K-dependent coagulation factors (factors II, VII, and X) results in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Phenindione
Synonyms: Not Available
Drug Category: Anticoagulants
Drug Type: Small Molecule; Approved
Other Brand Names containing Phenindione: Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Hedulin; Hemolidione; Indema; Indion; Indon; PID; Phenhydren; Phenillin; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol;
Absorption: Absorbed slowly from the gastrointestinal tract.
Toxicity (Overdose): Oral, mouse: LD50 = 175 mg/kg; Oral, rat: LD50 = 163 mg/kg.
Protein Binding: 88%
Biotransformation: Hepatic.
Half Life: 5-10 hours
Dosage Forms of Diophindane: Not Available
Chemical IUPAC Name: 2-phenylindene-1,3-dione
Chemical Formula: C15H10O2
Phenindione on Wikipedia: http://en.wikipedia.org/wiki/Phenindione
Organisms Affected: Humans and other mammals

Danilon Equidos 1

Danilon Equidos 1.5 g Granules for top dressing

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Danilon Equidos 1.5 g Granules for top dressing

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 10 g sachet contains

Active substanceg
Suxibuzone (microencapsulated) 1.5

Excipient(s):
Quinoline yellow (E 104) 0.0025

For a full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Granules for top dressing use.
Yellow and odourless granules.

4. CLINICAL PARTICULARS
4.1 Target species
Equines.

4.2 Indications for use
Treatment of pain and inflammation associated with musculo-skeletal conditions in the horse eg osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.

4.3 Contra-indications
Do not administer to animals with renal, hepatic or cardiac disorders; where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Avoid use in dehydrated, hypovolemic or hypotensive animals as there is an increased risk of renal failure.

4.4 Special warnings for each target species
Do not administer to horses prior to taking part in a competition.

During treatment of very young animals (less than 12 weeks) where development of their hepatic or renal function may be incomplete, or in aged animals which may have these functions impaired, as well as in ponies, additional risk may be involved. In these cases, doses should be accurately calculated and patients monitored closely.

During treatment, do not restrict the consumption of water. Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there may be an increased risk of renal failure.

NSAIDs can cause inhibition of phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infections appropriate antimicrobial therapy should be instigated.

4.5 Special precautions for use
Special precautions for use in animals
During treatment do not restrict the consumption of water.

Use in very young or aged animals and ponies may involve additional risk. Adjust the dose to bodyweight and closely monitor clinical response.

Do not exceed the stated dose or duration of treatment. Dosage should be kept to a minimum for alleviation of symptoms.

Special precautions to be taken by the person administering the product to the animals
Wear suitable gloves. Wash hands after use.
Use in a well-ventilated area. Avoid inhaling any dust when opening sachet and mixing with feed. In case of accidental contact with eyes, wash immediately with plenty of clean water. In case of accidental ingestion, seek medical advice immediately and show this label to the physician.

4.6Adverse reactions (frequency and seriousness)
After continued use, or at high doses gastro-intestinal changes may occur. Occasionally blood dyscrasias and renal alterations may be found, especially in animals with restricted access to water.

4.7 Use during pregnancy and lactation
Studies have not been carried out in the horse to establish safe use during pregnancy and lactation.

4.8 Interaction with other veterinary medicinal products and other forms of interaction
Suxibuzone and its metabolites may be highly bound to plasma proteins and compete with other highly bound drugs eg sulphonamides, warfarin; or it may itself be displaced to produce an increase of non-bound pharmacologically active concentrations which could lead to toxic effects. Drug compatibility must be closely monitored when adjunctive therapy is required.

Do not administer together with other NSAIDs concurrently or within 24 hours of each other.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

4.9 Amounts to be administered and administration route
For oral administration.
When added to a portion of feed the product will be accepted by most horses.

The following should be used as a guide, according to individual response:
Horses
For a 480 kg bodyweight horse, the contents of 2 sachets should be administered twice daily (equivalent to 12.5 mg of suxibuzone/kg/day) for 2 days, followed by 1 sachet twice daily (6.25 mg of suxibuzone/kg/day) for 3 days.

Thereafter, 1 sachet daily (3.1 mg of suxibuzone/kg/day) or on alternate days, or the minimum dose necessary for a satisfactory clinical response.

Ponies
Ponies should receive only half the dose rate recommended for horses.
For a 240 kg bodyweight pony, the contents of 1 sachet should be administered daily (equivalent to 6.25 mg of suxibuzone/kg/day) for 2 days, followed by 1/2 sachet daily (3.1 mg of suxibuzone/kg/day) for 3 days or 1 sachet on alternate days.
Thereafter, reduce the dose to the minimum dose necessary for a satisfactory clinical response.

For administration of less than one sachet, use the measuring scoop provided. One full level scoop contains 5 g granules (equivalent to 1/2 sachet) and up to the green line level contains 2,5 g granules (equivalent to 1/4 sachet).

Hay, as part of the diet, may delay the absorption of suxibuzone and so the onset of clinical effect. It is advisable not to feed hay immediately prior to, or with DANILON equidos.

If no clinical response is evident after 4-5 days, discontinue treatment and reconsider the diagnosis.

4.10 Overdose (symptoms, emergency procedures, antidotes)

In case of accidental continuous overdose, the following symptoms may be observed:

  • Thirst, depression, anorexia and weight loss
  • Gastrointestinal disorders (irritation, ulcers, diarrhoea and blood in the faeces)
  • Altered blood profiles and haemorrhages
  • Hypoproteinemia with ventral oedema causing hemoconcentration, hypovolemic shock and circulatory collapse.
  • Renal failure and fluid retention.

If signs of intolerance appear, discontinue treatment and establish symptomatic therapy.
A slow intravenous perfusion of a solution of sodium bicarbonate, which leads to urine alkalinisation, increases the clearance of the product.

4.11 Withdrawal periods
Not to be used in animals intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antiinflamatory and Antirheumatic Products, Non-steroids
ATC vet code. QM01AA90

5.1 Pharmacodynamic properties
Suxibuzone is a Non-Steroidal Anti-inflammatory Drug (NSAID) synthetically derived from pyrazolone with anti-inflamma­tory, antipyretic and analgesic properties with low ulcerogenic potential.

When mixed with concentrate feed, the product was shown to be palatable to horses.

Its mechanism of action is based on the inhibition of the cyclooxygenase (enzyme which catalyzes the synthesis of prostaglandins, prostacyclines and thromboxanes from arachidonic acid). The therapeutic effects are mainly due to the inhibition of the biosynthesis of prostaglandi­nes, which act as peripheral mediators of pain and trigger the synthesis of endogen pyrogens and mediators in the inflammatory process. It also inhibits platelet aggregation.

The therapeutic effect of suxibuzone relies entirely on the activity of its active metabolites. Strong anti-inflammatory activity has been shown for phenylbutazone and oxyphenbutazone. The third metabolite g-hydroxyphenbutazone is considered to be pharmacologically inactive.

5.2 Pharmacokinetic properties
After oral administration suxibuzone is readily absorbed and most of it is metabolised by the hepatic microsomal system producing phenylbutazone, oxyphenbutazone and g-hydroxyphenylbutazone. No unaltered parent compound can be detected in plasma after oral administration of suxibuzone to horses. These active metabolites have a high degree of affinity for plasma proteins and are eliminated mainly through urine, as glucoronide conjugates, but also, in a small percentage, through faeces. Less than 1% is eliminated through saliva and milk.

After the administration of a single 6.25 mg/kg oral dose of the parent compound phenylbutazone reaches its maximum plasma concentration (10 µg/ml) at 4-5- hours after administration with an elimination half life of 5-6 h. Oxyphenbutazone reaches its maximum (2.1 µg/ml) at 15 hours after administration.

As happens with other NSAID´s the duration of the clinical response is much longer than the plasma half-life. Significant concentrations of both active metabolites are found in synovial fluid for at least 24 hours after administration.

6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients

Quinoline yellow (E 104)
Mannitol
Sucrose
Povidone K-30
Sodium saccharin
Ethyl Cellulose 20

6.2 Incompatibilities
None known.

6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 4 years
Shelf life after first opening of the sachet: 7 days.

6.4 Special precautions for storage
After opening a sachet re-seal as well as possible between doses. Once opened, use within 7 days.
This medicinal product does not require any special storage conditions.

6.5 Nature and composition of immediate packaging
Carton containing 18 x 10 g or 60 x 10 g laminated opaline/aluminium polyethylene sachets with 5 g scoop (when level) and 2.5 g increment dosing device.
Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste material, if any
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Additional information Tips

Why is it important adding more products to http://wwww.ekavet.com database?
When You buy advertising campaign You pay the money and get new customers, but if You cease to pay, Your site attendance also decreases.

Place Your product adds on sites like http://www.ekavet.com Your product ad will be always visible to everyone, plus it is free and without expiry.

And so, the more products You will have in our database, the more Your products will be visible on our website and the more good back links to Your website You will have. Don't wait, place Your ads today and get new customers tomorrow.

Terms and Conditions Privacy Policy
© 2013-2015 ekavet.com. All Rights Reserved

Noroxin (Danilon) Delivery

You can order delivery of a Noroxin (Danilon) to the Spain, Puerto Rico, Germany or any other country in the world. Residents of the USA can order Noroxin (Danilon) to any city, to any address, for example to Omaha, San Jose, Knoxville or Scottsdale.